

REMARKS/ARGUMENTS

Claims 1-5 are active.

Claim 1 is limited to enterolactone (ENL), which the Examiner has indicated as being suitably described by the specification. See page 2 of the Action. Accordingly, the written description rejection is no longer applicable.

Claims 3 and 4 have been amended to remove the multiple dependency.

No new matter is added.

The rejection of Claims 1-5 under 35 USC 102(b) citing Ahoptupa in view of Pezzuto is no longer applicable. While Ahotupa teaches that HMR is a precursor to the ENL metabolite Ahotupa does not describe or suggest a composition specifically with ENL specified in Claim 1. Indeed, Ahotupa describes compositions for administration to a person that comprises hydromatairesinol (HMR), isomers, stereoisomers and salts thereof.

Accordingly, Ahoptupa does not anticipate the claims pending in this application.

Withdrawal of the rejection is requested.


Application No. 10/572,945

Reply to Office Action of the Official Action of March 31, 2010

A Notice of Allowance for all pending claims is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, L.L.P.

A handwritten signature in black ink, appearing to be 'Daniel J. Pereira', is written over a horizontal line.

Daniel J. Pereira
Attorney of Record
Registration No. 45,518

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 07/09)